1035 related articles for article (PubMed ID: 27039128)
1. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
Chin KL; Zomer E; Wang BH; Liew D
Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
[TBL] [Abstract][Full Text] [Related]
3. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction.
Gaziano TA; Fonarow GC; Velazquez EJ; Morrow DA; Braunwald E; Solomon SD
JAMA Cardiol; 2020 Nov; 5(11):1236-1244. PubMed ID: 32785628
[TBL] [Abstract][Full Text] [Related]
5. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
6. Cost-Utility Analysis of Sacubitril-Valsartan Compared with Enalapril Treatment in Patients with Acute Decompensated Heart Failure in Thailand.
Krittayaphong R; Permsuwan U
Clin Drug Investig; 2021 Oct; 41(10):907-915. PubMed ID: 34533783
[TBL] [Abstract][Full Text] [Related]
7. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation: The PARADIGM-HF Trial.
Solomon SD; Claggett B; Packer M; Desai A; Zile MR; Swedberg K; Rouleau J; Shi V; Lefkowitz M; McMurray JJV
JACC Heart Fail; 2016 Oct; 4(10):816-822. PubMed ID: 27395349
[TBL] [Abstract][Full Text] [Related]
9. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
[TBL] [Abstract][Full Text] [Related]
10. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
Curtain JP; Adamson C; Docherty KF; Jhund PS; Desai AS; Lefkowitz MP; Rizkala AR; Rouleau JL; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJV
JACC Heart Fail; 2023 Jul; 11(7):749-759. PubMed ID: 37407154
[TBL] [Abstract][Full Text] [Related]
11. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
[TBL] [Abstract][Full Text] [Related]
13. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
Rohde LE; Claggett BL; Wolsk E; Packer M; Zile M; Swedberg K; Rouleau J; Pfeffer MA; Desai AS; Lund LH; Kober L; Anand I; Merkely B; Senni M; Shi V; Rizkala A; Lefkowitz M; McMurray JJV; Solomon SD
Circ Heart Fail; 2021 Mar; 14(3):e008052. PubMed ID: 33706551
[TBL] [Abstract][Full Text] [Related]
14. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
McMurray JJ
Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
[TBL] [Abstract][Full Text] [Related]
16. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
17. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial.
Desai AS; Solomon S; Claggett B; McMurray JJ; Rouleau J; Swedberg K; Zile M; Lefkowitz M; Shi V; Packer M
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296397
[TBL] [Abstract][Full Text] [Related]
18. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
McMurray JJ; Packer M; Desai AS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau J; Shi VC; Solomon SD; Swedberg K; Zile MR;
Eur J Heart Fail; 2013 Sep; 15(9):1062-73. PubMed ID: 23563576
[TBL] [Abstract][Full Text] [Related]
19. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S; Andries G; Biswas M; Khera S
Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
[TBL] [Abstract][Full Text] [Related]
20. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Lillyblad MP
Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
